Suche

Close

FimmCyte – novel endometriosis treatment

Redaktion

The project management is responsible for the content of the information provided.

Projektdaten

  • Projekt-Nr: GRS-095/21 
  • Förderbeitrag: CHF 150'000 
  • Bewilligung: 10.02.2022 
  • Dauer: 05.2022 - 09.2023 
  • Handlungsfeld:  InnoBooster, seit 2018

Projektleitung

Projektbeschreibung

At FimmCyte our vision is to develop the first disease modifying treatment for endometriosis. Every tenth woman has endometriosis, but besides pain management and surgery there are no alternatives. At FimmCyte we have developed a novel therapy which has proven to be highly effective in animal and ex-vivo models. This is the first immune based therapy for endometriosis and once successful will provide patients and healthcare providers a much-needed tool to fight this painful disease.

Stand/Resultate

The support by Gebert Rüf foundation allowed us to advance our asset closer to first in human. After reaching a frozen design FimmCyte will seek to conduct first in-human studies by 2026. The team has been successful in securing prestigious accelerators support such as VentureKick III and the Bioinnovation institute bolstering FimmCyte’s position as a pioneer in the field of women’s health.

Links

FimmCyte Website | LinkedIn
FimmCyte News
Impact Clip

Five latest advancements in endometriosis research, Labiotech, 30.5.2023
FimmCyte joins BaseLaunch Portfolio, Baselaunch, 30.3.2023
To Cure Endometriosis, Women Need More Than A Month Of Awareness, Forbes, 28.3.2023
Meet the start-ups: FimmCyte, BioInnovation Institute, 20.9.2022

Am Projekt beteiligte Personen

Mohaned Shilaih, PhD, co-founder
Valentina Vongrad, PhD, co-founder
Prof. Brigitte Leeners, Department Head Reproductive Endocrinology

Letzte Aktualisierung dieser Projektdarstellung  29.10.2024